STOCK TITAN

Lexicon Pharmaceuticals Inc - LXRX STOCK NEWS

Welcome to our dedicated news page for Lexicon Pharmaceuticals (Ticker: LXRX), a resource for investors and traders seeking the latest updates and insights on Lexicon Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Lexicon Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Lexicon Pharmaceuticals's position in the market.

Rhea-AI Summary
LXRX - Lexicon Pharmaceuticals, Inc. to Present at Jefferies London Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Summary
LXRX: Lexicon Pharmaceuticals reports Q3 progress with the commercial launch of INPEFA® (sotagliflozin) for heart failure treatment and the advancement of LX9211 for diabetic peripheral neuropathic pain. The company achieved important milestones in increasing demand and formulary inclusions, paving the way for further commercial acceleration into 2024 and beyond.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.8%
Tags
earnings
-
Rhea-AI Summary
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) will release its Q3 2023 financial results on November 8th, 2023. A conference call and live webcast will be conducted at 8:00 a.m. ET to discuss the financial results and provide a business update. Dial-in and replay information provided.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.71%
Tags
conferences earnings
Rhea-AI Summary
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) will present five data sets related to INPEFA® (sotagliflozin) at the American Heart Association Scientific Sessions 2023. Two of the presentations will focus on the early clinical benefit and cost-effectiveness metrics of INPEFA for heart failure. The company aims to demonstrate the clinical and economic value of INPEFA.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.48%
Tags
none
-
Rhea-AI Summary
Express Scripts has listed INPEFA as a preferred product on Medicare national formularies starting November 1, 2023. INPEFA has been approved by the FDA for the treatment of heart failure. This decision will provide access to INPEFA for Express Scripts commercial and Medicare patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.06%
Tags
none
-
Rhea-AI Summary
Lexicon Pharmaceuticals, Inc. announces the appointment of Matthew Cullen as vice president of value and access and Lisa DeFrancesco as head of investor relations and corporate strategy. Cullen brings over 35 years of industry experience, previously leading market access launches at Apellis Pharmaceuticals and Bristol-Myers Squibb. DeFrancesco has nearly 25 years of experience in investor relations and corporate communications, most recently at Amarin Pharma. Their expertise will support the launch of INPEFA® in heart failure and the development of LX9211.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.06%
Tags
none
Rhea-AI Summary
Lexicon Pharmaceuticals, Inc. will present data from four studies on sotagliflozin at the American Society of Nephrology Kidney Week Annual Meeting. The studies focus on the efficacy and safety of sotagliflozin in patients with type 1 diabetes and chronic kidney disease, the effects of sotagliflozin on anemia in patients with type 2 diabetes and CKD, and the concordance between laboratory- and ICD-10 code-defined stages of CKD among heart failure patients. The FDA recently approved sotagliflozin for the treatment of heart failure.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.33%
Tags
none
-
Rhea-AI Summary
Lexicon Pharmaceuticals highlights positive financial impact of INPEFA (sotagliflozin) in upcoming presentations at the Academy of Managed Care Pharmacy (AMCP) Nexus 2023 National Meeting
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4%
Tags
none
-
Rhea-AI Summary
Lexicon Pharmaceuticals announces studies on cost-effectiveness and budget impact of INPEFA at AMCP Nexus 2023 National Meeting
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.46%
Tags
none
Rhea-AI Summary
INPEFA approved by FDA and listed as preferred product on Medicare formularies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12%
Tags
none
Lexicon Pharmaceuticals Inc

Nasdaq:LXRX

LXRX Rankings

LXRX Stock Data

539.26M
100.03M
1.65%
77.58%
8.63%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
The Woodlands

About LXRX

corporate overview lexicon pharmaceuticals is a biopharmaceutical company that has harnessed the power of genetics for drug discovery. our research team has generated a pipeline of novel drug candidates in clinical development across a broad range of indications. the genome: our source of discovery we have applied gene knockout technology to thousands of potential drug targets encoded in the human genome. our scientists have gained a thorough understanding of target biology and identified new points of intervention for future therapies. we have integrated a series of recombinant dna and chemistry technologies into a systematic drug discovery and development process. our unique knowledge of targets from the human genome has allowed us to better evaluate and advance novel drug candidates with great promise for patients. a diverse pipeline of targeted therapies our genomics-based approach to drug discovery has enabled our scientists to select drug targets across a broad range of indicatio